Sunshine Biopharma, Inc. (SBFMW) Stock Analysis

Company Overview

Sunshine Biopharma, Inc. operates as a pharmaceutical entity dedicated to the research and development of life-saving medicines across various therapeutic areas, with a specific focus on oncology and antivirals within the United States and Canadian markets. The company functions through its Prescription Generic Pharmaceuticals and Nonprescription segments, aiming to deliver essential healthcare solutions. Although specific sector and industry classifications are not publicly listed for this entity, its operational focus on generic pharmaceuticals places it within the broader healthcare and biotechnology landscape where cost-effective treatments are critical. The company currently employs 52 individuals and reports a trailing twelve-month revenue of $37.32 million, while its market capitalization and price-to-sales ratio are not disclosed in available data. These financial figures indicate that Sunshine Biopharma is a small-cap organization operating with a lean workforce, suggesting a capital-light structure typical of early-stage or niche pharmaceutical developers that prioritize research expansion over large-scale commercial infrastructure.

Financial Health

The company reported a revenue of $37.32 million over the trailing twelve months, yet this top-line growth resulted in a net income of -$5,992,637 and an EBITDA of -$4,559,393. The significant gap between the positive revenue of $37.32 million and the negative net income of -$5,992,637 reveals a cost structure where operating expenses and research costs substantially exceed gross profits, which is characteristic of companies in the research and development phase. Free cash flow stands at -$6,501,533, indicating that the company is burning cash to fund its operations and development pipeline rather than generating liquidity from its current business activities. This negative cash flow position limits immediate financial flexibility but is often a calculated necessity for pharmaceutical firms investing heavily in clinical trials and drug formulation. The gross margin is 33.0%, which suggests that the company retains nearly one-third of its revenue after direct production costs, yet this is insufficient to cover broader operational overheads. The operating margin is -5.6% and the profit margin is -16.1%, indicating that for every dollar of revenue, the company incurs a loss in both operational efficiency and overall profitability. Total cash on hand is $9.31 million, which exceeds the total debt of $854,761, providing a cushion of approximately $8.46 million in net cash, though the debt-to-equity ratio is reported at 3.53, suggesting a leveraged balance sheet relative to equity. The current ratio is 4.21, which indicates a robust short-term liquidity position where current assets are more than four times the current liabilities, ensuring the ability to meet obligations as they come due. Return on equity is -24.3% and return on assets is -9.9%, metrics that reveal management is currently utilizing the company's capital base to generate losses rather than returns, reflecting the high-risk nature of their development activities.

Valuation Assessment

Trailing and forward P/E ratios are both listed as not available due to the company's negative earnings, which prevents the calculation of traditional earnings-based valuation multiples. The price-to-book ratio is 0.03, a figure that indicates the market is valuing the company at a fraction of its book value, suggesting significant intangible assets or potential issues not fully captured on the balance sheet. Price-to-sales and EV/EBITDA multiples are not available for analysis in the current reporting period, meaning investors must rely on alternative metrics like the price-to-book ratio to gauge relative value. The stock has a 52-week high of $0.14 and a 52-week low of $0.14, meaning the current trading price is exactly equal to both the high and low, implying the stock has experienced no price movement or volatility over the past year. The beta value is 1.64, which signifies that the stock's price volatility is 64% higher than the broader market, indicating high sensitivity to market fluctuations and increased risk for risk-averse investors.

Growth & Income

Revenue growth year-over-year is 11.6%, demonstrating a positive trajectory in sales despite the company's overall unprofitability, while earnings growth is not available due to negative earnings. The divergence between positive revenue growth and the absence of positive earnings growth implies that top-line expansion is currently being consumed by rising costs or continued investment in development rather than translating into bottom-line profitability. As the company does not pay dividends, there is no dividend yield or payout ratio to evaluate for income generation, meaning the company reinvests all available earnings back into its research and development operations rather than distributing cash to shareholders. The overall growth and income profile is characterized by top-line expansion funded by cash reserves, with no current income stream for investors and a reliance on future commercialization success to achieve profitability.